Pfizer Signs a WW License Agreement with Pyxis to Develop and Commercialize Two ADC Candidates
Shots:
- Pfizer to receive an up front- equity in Pyxis and is eligible for development & commercial milestones as well as royalties on potential sales of ADCs
- Pyxis gets a WW license to develop and commercialize PYX-201 and PYX-203. Pfizer will continue to support the development and advancement of ADCs portfolio via an equity investment
- Additionally- Pyxis get the license to Pfizer’s ADC platform that will expand its ADC portfolio and further strengthen its developmental capabilities
Ref: Businesswire | Image: PRNewswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
